Sun Pharma announced that UNLOXCYT (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network (NCCN) Category 2A recommended option for patients with locally advanced Cutaneous Squamous Cell Carcinoma (laCSCC) who are not candidates for curative surgery orcurative radiation.

This is an addition to the Category 2A designation in metastatic Cutaneous Squamous Cell Carcinoma (mCSCC), which was assigned to UNLOXCYT in 2025.

UNLOXCYT was approved by the US Food and Drug Administration (FDA) in 2024 and is indicated for the treatment of adults with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation. The recommended dosage of UNLOXCYT is 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks. UNLOXCYT is the first and only FDA approved PD-L1-blocking antibody for advanced CSCC (aCSCC).

The evidence submitted to NCCN in support of the change was based on the pivotal registration study, in which 55 percent of patients achieved an objective response, including 26 percent who achieved a complete response. Responses were durable: at a median follow-up of 24.1 months; median Duration of Response (DoR) had not been reached (range: 8.3 to 31.3+ months). In addition, fewer than 1 percent of patients experienced a high-grade (Grade 3-5) immune-mediated Adverse Reaction (imARs)—an important consideration in this patient population. There were no grade 4 or 5 imARs.

Ahmad Naim, MD, Senior Vice President, North American Chief Medical Officer, Sun Pharma, said, “The NCCN Guidelines play an important role in helping physicians evaluate appropriate treatment options for patients across different disease settings. The elevation of UNLOXCYT to a Category 2A recommendation for patients with laCSCC marks an important milestone, validating the growing body of clinical evidence supporting UNLOXCYT and reflecting increasing confidence among oncology experts in its role as a treatment option for patients with this challenging disease.”

NCCN is an alliance of 34 leading cancer centers in the US. Its Clinical Practice Guidelines in Oncology, referred to as the NCCN Guidelines, provide recommendations for the prevention, diagnosis, evaluation, and treatment of different types of cancer. The NCCN Guidelines are among the most influential clinical guidelines in cancer care, offering evidence-based, expert developed recommendations intended to help clinicians make treatment decisions for patients with cancer.

One such expert clinician is Dr. Francis Worden, Clinical Professor of Internal Medicine at the University of Michigan Rogel Cancer Center, whose institution is one of the 34 NCCN member cancer centers in the alliance.

Dr. Worden said, “This guideline update reflects the strength of the published evidence supporting the use of UNLOXCYT as first line treatment for laCSCC. In the pivotal study, patients experienced durable and clinically meaningful responses. UNLOXCYT also demonstrated a low incidence of high-grade imARs—an important consideration when selecting immune checkpoint inhibitor therapy for a patient population that is mainly elderly and is often afflicted with other health issues. These clinical outcomes may be explained by the mechanism of action that restores adaptive immunity, engages innate immunity through Antibody-Dependent Cellular Cytotoxicity (ADCC), and preserves PD-L2 signaling that may be linked to the presence of some immune tolerance in non-tumor tissues.”

NCCN Guidelines also have a meaningful impact on patient access because they inform payer coverage policies, prior-authorisation criteria, institutional formularies, and clinical pathways.

Mark Gimbert, Senior Vice President, Head of Market and Patient Access, North America, Sun Pharma, said, “For patients with laCSCC—many of whom are older, medically complex, and vulnerable to treatment-related complications—access to a therapy that offers durable responses together with a low rate of high-grade imARs is especially important. NCCN recognition helps ensure that appropriate patients can receive this treatment up front without unnecessary access barriers.”